Australia’s Therapeutic Goods Administration (TGA) determined that Covaxin (manufactured by Bharat Biotech, India) and BBIBP-CorV (manufactured by Sinopharm, China) vaccines would be 'recognized' to establish a traveler’s vaccination status.
This recognition announced on November 1, 2021, is for travelers aged 12 and over who have been vaccinated with Covaxin and those 18 to 60 who have been immunized with BBIBP-CorV.
Australia Accepts China and India COVID-19 Vaccinated Travelers
U.S. FDA Reviews Heart Health Risks from mRNA Vaccine
Massachusetts based Moderna, Inc. provided an update on October 31, 2021, that the U.S. Food and Drug Administration (FDA) had notified the Company that it would require additional time to complete its assessment of Moderna’s recent Emergency Use Authorization (EUA) request.
The new EUA request is for the use of the Moderna COVID-19 vaccine (mRNA-1273) at the 100 µg dose level in adolescents 12 to 17 years of age.
Postacute COVID-19 Syndrome May Affect Physical, Cognitive Function
Increased levels of fatigue and dyspnea, decreased levels of physical activity reported; 63 percent showed at least mild cognitive impairment
CDC Panel Signs Off on Pfizer Vaccine for Younger Children
Children ages 5 to 11 years can now receive one-third of the adult dose, with two injections given three weeks apart
‘Delta Plus’ Variant Surfaces in Eight U.S. States
AY.4.2 ‘sub-lineage’ of delta may spread faster than the original variant, but there is no evidence that it causes more severe illness
EHR Data Support Reported Effectiveness of Ad26.COV2.S Vaccine
Retrospective study showed incidence rate ratio of 0.26 for SARS-CoV-2 infection in vaccinated persons versus unvaccinated controls